Alnylam Pharmaceuticals (ALNY) EBIT (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly EBIT came in at $231.4 million in Q2 2026, up 1528.74% YoY from $14.2 million in Q2 2025, and down 13.85% on a QoQ basis from $268.6 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) EBIT (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of EBIT data on file, last reported at $231.4 million in Q2 2026.
- Quarterly EBIT rose 1528.74% year-over-year to $231.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $999.8 million (up 654.86% YoY) and the FY2025 annual result came in at $501.6 million, up 383.56% from the prior year.
- EBIT fell to $231.4 million in Q2 2026, from $268.6 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $368.0 million in Q3 2025 to a low of -$258.0 million in Q3 2022.
- A 5-year average of -$13.5 million and a median of -$60.2 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT sank 135.96% — and 2026, when it soared 1528.74%.
- Tracing ALNY's EBIT over 5 years: stood at -$188.6 million in 2022, then jumped by 38.28% to -$116.4 million in 2023, then climbed by 9.66% to -$105.2 million in 2024, then soared by 225.26% to $131.7 million in 2025, then jumped by 75.71% to $231.4 million in 2026.
- The last three EBIT figures came in at $231.4 million (Q2 2026), $268.6 million (Q1 2026), and $131.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 231.44 Mn |
| Mar 31, 2026 | 268.64 Mn |
| Dec 31, 2025 | 131.72 Mn |
| Sep 30, 2025 | 367.98 Mn |
| Jun 30, 2025 | -16.20 Mn |
| Mar 31, 2025 | 18.08 Mn |
| Dec 31, 2024 | -105.16 Mn |
| Sep 30, 2024 | -76.91 Mn |
| Jun 30, 2024 | 48.61 Mn |
| Mar 31, 2024 | -43.44 Mn |
| Dec 31, 2023 | -116.40 Mn |
| Sep 30, 2023 | 213.87 Mn |
| Jun 30, 2023 | -229.83 Mn |
| Mar 31, 2023 | -149.81 Mn |
| Dec 31, 2022 | -188.61 Mn |
| Sep 30, 2022 | -258.04 Mn |
| Jun 30, 2022 | -191.69 Mn |
| Mar 31, 2022 | -146.73 Mn |
| Dec 31, 2021 | -194.56 Mn |
| Sep 30, 2021 | -181.68 Mn |